Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells

Abstract In a search for potentially tumour-specific MHC-class-II-restricted antigens, the immunogenicity of endogenous peptides that had been eluted from HLA-DR molecules of the human melanoma cell line FM3 (HLA-DRB1*02x, DRB1*0401) was tested in vitro. Two 16-mers representing gp100 positions 44–59, and annexin II positions 208–223 bound well to isolated DRB1*0401 molecules and are discussed here. HLA-DR-matched normal donors' T cells were cultured with peptide-pulsed artificial antigen-presenting cells (CHO cells cotransfected with genes for HLA-DRB1*0401 and CD80 and coexpressing high levels of both human molecules). Specific sensitization was achieved against both peptides, as measured in assays of autocrine proliferation and interleukin-2 secretion. Moreover, responses to native autologous melanoma cells but not to autologous B cells were also observed. In view of the expression of fas by the activated T cells and of fas ligand by the melanoma cells, blockade of potential fas/fas-ligand interactions was undertaken using monoclonal antibodies (mAb). The antagonistic fas-specific mAb M3, but not the fas agonist M33, caused a markedly enhanced T cell response to FM3 cells. These results demonstrate that synthetic peptide antigens are able to sensitize T cells in vitro for effective MHC-class-II-restricted recognition of melanoma cells.

[1]  B. Dréno,et al.  HLA class II‐restricted recognition of common tumor epitopes on human melanoma cells by CD4+ melanoma‐infiltrating lymphocytes , 1995, European journal of immunology.

[2]  C. Viret,et al.  Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma‐infiltrating lymphocytes , 1992, European journal of immunology.

[3]  M. Hollingsworth,et al.  Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers. , 1993, Carcinogenesis.

[4]  H. Rammensee,et al.  Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. , 1990, Science.

[5]  C. Melief,et al.  Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. , 1995, Leukemia.

[6]  P. Galle,et al.  Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.

[7]  S. Ostrand-Rosenberg.  Tumor immunotherapy: the tumor cell as an antigen-presenting cell. , 1994, Current opinion in immunology.

[8]  A Sette,et al.  Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes , 1996, The Journal of experimental medicine.

[9]  S. Rosenberg,et al.  Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Yutaka Kawakami,et al.  Human tumor antigens recognized by T-cells , 1997, Immunologic research.

[11]  E. Thorsby,et al.  T cell clones specific for p21 ras‐derived peptides: Characterization of their fine specificity and HLA restriction , 1993, European journal of immunology.

[12]  C. Melief,et al.  Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. , 1996, Blood.

[13]  G. Pawelec,et al.  BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. , 1996, Blood.

[14]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[15]  C. Viret,et al.  Defective lymphokine production by most CD8+ and CD4+ tumor‐specific T cell clones derived from human melanoma‐infiltrating lymphocytes in response to autologous tumor cells in vitro , 1994, European journal of immunology.

[16]  G. Pawelec,et al.  Interleukin 10 protects activated human T lymphocytes against growth factor withdrawal-induced cell death but only anti-fas antibody can prevent activation-induced cell death. , 1996, Cytokine.

[17]  S. Rosenberg,et al.  Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha in response to autologous tumor stimulation. , 1993, Blood.

[18]  H. Rammensee,et al.  Identification of classical minor histocompatibility antigen as cell-derived peptide , 1990, Nature.

[19]  J. Zeuthen,et al.  Differential modulation by interferon γ of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens , 1996, Cancer Immunology, Immunotherapy.

[20]  S. Rosenberg,et al.  Melanoma‐specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by epstein‐barr virus‐transformed B cells , 1994, International journal of cancer.

[21]  H. Rammensee,et al.  Chemistry of peptides associated with MHC class I and class II molecules. , 1995, Current opinion in immunology.

[22]  M. Rosenblum,et al.  Developmental regulation of annexin II (Lipocortin 2) in human brain and expression in high grade glioma. , 1992, Cancer research.

[23]  E. Thorsby,et al.  Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study , 1996, International journal of cancer.

[24]  F. Sinigaglia,et al.  Promiscuous and allele-specific anchors in HLA-DR-binding peptides , 1993, Cell.

[25]  S. Nagata.  Fas ligand and immune evasion , 1996, Nature Medicine.

[26]  S. Topalian,et al.  MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. , 1994, Current opinion in immunology.

[27]  G. Pawelec,et al.  The Role of Endogenous Peptides in the Direct Pathway of Alloreactivity to Human MHC Class II Molecules Expressed on CHO Cells , 1996, Immunological reviews.

[28]  J. Myklebust,et al.  Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21‐ras (12VAL) peptide vaccination of a patient, recognize 12VAL‐dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation , 1997, International journal of cancer.

[29]  Wei Chen,et al.  Immunity to Oncogenic Proteins , 1995, Immunological reviews.

[30]  H. Rammensee,et al.  Limit of T cell tolerance to self proteins by peptide presentation. , 1990, Science.

[31]  C. Smith,et al.  Fas ligand mediates activation-induced cell death in human T lymphocytes , 1995, The Journal of experimental medicine.

[32]  E. Thorsby,et al.  Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination. , 1996, British Journal of Cancer.

[33]  S. Rosenberg,et al.  Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. , 1991, Journal of immunology.

[34]  H. Schulze‐Bergkamen,et al.  Specificities and functions of CD4+ HLA class II-restricted T cell clones against a human sarcoma: evidence for several recognized antigens. , 1996, Journal of immunology.

[35]  P. Pandolfi,et al.  Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. , 1993, Blood.

[36]  D. Sansom,et al.  B7/CD28 but not LFA-3/CD2 interactions can provide 'third-party' co-stimulation for human T-cell activation. , 1993, Immunology.

[37]  G. Pawelec,et al.  Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. , 1997, Cancer research.

[38]  T. Mak,et al.  T cell responses are governed by avidity and co‐stimulatory thresholds , 1996, European journal of immunology.

[39]  F. Shanahan,et al.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.